Mi az ára ARYx Therapeutics, Inc. (ARYX)

ARYx Therapeutics, Inc. (ARYX) ára $0.0005

Mi a ARYx Therapeutics, Inc. (ARYX piaci tőkésítése)

ARYx Therapeutics, Inc. piaci tőkésítése (ARYX) $16.73K

ARYx Therapeutics, Inc. (ARYX) Ár és Piaci Kapitalizáció

Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc. is dedicated to discovering and advancing innovative treatments, primarily focusing on widespread, chronic conditions addressable with oral medications. The company utilizes its unique RetroMetabolic Drug Design technology to engineer distinctive molecular compounds that maintain the therapeutic effectiveness of their original counterparts. Its clinical development portfolio includes several promising candidates: Tecarfarin (ATI-5923): An oral anticoagulant currently in Phase III clinical trials, aimed at preventing hazardous blood clots in at-risk patients. Budiodarone (ATI-2042): An oral antiarrhythmic agent undergoing Phase IIb development for managing atrial fibrillation, a form of irregular heart rhythm. ATI-7505: An oral prokinetic agent in Phase IIb clinical development, targeting various gastrointestinal issues such as chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease. ATI-9242: An antipsychotic agent progressing through Phase I clinical trials for the treatment of schizophrenia and other psychiatric conditions. Additionally, ARYx Therapeutics is conducting early-stage research on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal ailments.

A ARYX ára	B aktíva	A B piaci tőkésítése	Eredmények
$160,880 $16.73K	NVDA	$5.383T	+32,175,957,463.80%
$132,191 $16.73K	AAPL	$4.423T	+26,438,295,302.18%
$124,331 $16.73K	GOOG	$4.160T	+24,866,232,636.13%
$109,477 $16.73K	MSFT	$3.663T	+21,895,408,644.25%
$86,403.35 $16.73K	AMZN	$2.891T	+17,280,669,288.56%

A ARYX ára

B aktíva

A B piaci tőkésítése

Eredmények

$160,880 $16.73K